PE20011084A1 - QUINOLINE DERIVATIVES AS ALPHA-2 ANTAGONISTS - Google Patents

QUINOLINE DERIVATIVES AS ALPHA-2 ANTAGONISTS

Info

Publication number
PE20011084A1
PE20011084A1 PE2001000208A PE2001000208A PE20011084A1 PE 20011084 A1 PE20011084 A1 PE 20011084A1 PE 2001000208 A PE2001000208 A PE 2001000208A PE 2001000208 A PE2001000208 A PE 2001000208A PE 20011084 A1 PE20011084 A1 PE 20011084A1
Authority
PE
Peru
Prior art keywords
alkyl
antagonists
alpha
alcoxy
halogen
Prior art date
Application number
PE2001000208A
Other languages
Spanish (es)
Inventor
Mia Engstrom
Antti Haapalinna
Siegried Wuster
Jukka Sallinen
Juha-Matti Savola
Lis Hoglund
Original Assignee
Orion Corp
Juvantia Pharma Ltd Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp, Juvantia Pharma Ltd Oy filed Critical Orion Corp
Publication of PE20011084A1 publication Critical patent/PE20011084A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE QUINOLONA DE FORMULA I ENTRE OTROS DONDE R1 ES H, ALQUILO C1-C6; R2 ES OH, HALOGENO, ALQUILO C1-C6, ALQUILO C1-C6, ALQUENILO C2-C6, ALCOXI C1-C6, HALO-ALQUILO C1-C6, NO2, NH2, ENTRE OTROS; A ES UN ANILLO BENCENO, CICLOALQUILO C5-C7; CUANDO A ES BENCENO CADA R3 ES OH, HALOGENO, ALQUILO C1-C6, ALQUENILO C2-C6, ALCOXI C1-C6, HALO-ALQUILO C1-C6, NO2, NH2; CUANDO A ES CICLOALQUILO C5-C7 CADA R3 ES OH, HALOGENO, ALQUILO C1-C6, ALCOXI C1-C6, ENTRE OTROS; R4 Y R5 JUNTO A N FORMAN EL GRUPO a DONDE X ES O, =NR6; R6 ES H, OH, NH2, ALQUILO C1-C6, ALQUENILO C2-C6, CN-ALQUILO C1-C6, ENTRE OTROS; Ra Y Rb SON H, OH, HALOGENO, ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6, ALCOXI C1-C6 ENTRE OTROS; m Y t SON 0-3. LOS COMPUESTOS DE FORMULA I SON ANTAGONISTAS DE LOS ADRENOCEPTORES ALFA-2 Y SON UTILES PARA EL TRATAMIENTO DE TRASTORNOS DEL SISTEMA NERVIOSO CENTRALREFERS TO COMPOUNDS DERIVED FROM QUINOLONE OF FORMULA I AMONG OTHERS WHERE R1 IS H, ALKYL C1-C6; R2 IS OH, HALOGEN, C1-C6 ALKYL, C1-C6 ALKYL, C2-C6 ALKYL, C1-C6 ALCOXY, C1-C6 HALO-ALKYL, NO2, NH2, AMONG OTHERS; A IS A BENZENE RING, C5-C7 CYCLOALKYL; WHEN A IS BENZENE EACH R3 IS OH, HALOGEN, C1-C6 ALKYL, C2-C6 ALKYL, C1-C6 ALCOXY, C1-C6 HALO-ALKYL, NO2, NH2; WHEN A IS C5-C7 CYCLOALKYL EACH R3 IS OH, HALOGEN, C1-C6 ALKYL, C1-C6 ALCOXY, AMONG OTHERS; R4 AND R5 TOGETHER WITH N FORM THE GROUP a WHERE X IS O, = NR6; R6 IS H, OH, NH2, C1-C6 ALKYL, C2-C6 ALKENYL, CN-C1-C6 ALKYL, AMONG OTHERS; Ra AND Rb ARE H, OH, HALOGEN, C1-C6 ALKYL, C2-C6 ALKENYL, C2-C6 ALKINYL, C1-C6 ALCOXY, AMONG OTHERS; m AND t ARE 0-3. THE FORMULA I COMPOUNDS ARE ANTAGONISTS OF ALPHA-2 ADRENOCEPTORS AND ARE USEFUL FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS

PE2001000208A 2000-03-01 2001-03-01 QUINOLINE DERIVATIVES AS ALPHA-2 ANTAGONISTS PE20011084A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20000480A FI20000480A0 (en) 2000-03-01 2000-03-01 Quinoline and naphthalene derivatives as alpha-2 antagonists

Publications (1)

Publication Number Publication Date
PE20011084A1 true PE20011084A1 (en) 2001-10-25

Family

ID=8557801

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000208A PE20011084A1 (en) 2000-03-01 2001-03-01 QUINOLINE DERIVATIVES AS ALPHA-2 ANTAGONISTS

Country Status (21)

Country Link
EP (1) EP1263733A2 (en)
JP (1) JP2003525274A (en)
KR (1) KR20020089372A (en)
CN (1) CN1468224A (en)
AR (1) AR034249A1 (en)
AU (1) AU2001239331A1 (en)
BR (1) BR0108816A (en)
CA (1) CA2400657A1 (en)
CZ (1) CZ20022880A3 (en)
EE (1) EE200200490A (en)
FI (1) FI20000480A0 (en)
HU (1) HUP0204458A3 (en)
IL (1) IL151093A0 (en)
MX (1) MXPA02008402A (en)
NO (1) NO20024159D0 (en)
PE (1) PE20011084A1 (en)
PL (1) PL357874A1 (en)
RU (1) RU2002125944A (en)
SK (1) SK12332002A3 (en)
WO (1) WO2001064645A2 (en)
ZA (1) ZA200206956B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1474401A2 (en) * 2002-02-05 2004-11-10 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
CA2480266C (en) * 2002-04-03 2011-07-12 Orion Corporation Use of an alpha2-adrenoreceptor antagonist for cns-related diseases
CA2480695A1 (en) 2002-04-03 2003-10-09 Orion Corporation Polycyclic compounds as potent alpha2-adrenoceptor antagonists
CN1304374C (en) * 2002-04-30 2007-03-14 永进药品工业株式会社 Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
WO2004067513A1 (en) * 2003-01-27 2004-08-12 Oy Juvantia Pharma Ltd Antagonists for alpha-2 adrenoceptors
ES2375929T3 (en) 2005-07-04 2012-03-07 High Point Pharmaceuticals, Llc HISTAMINE RECEIVER ANTAGONISTS H3.
WO2007053436A1 (en) 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
EP1968961A2 (en) 2005-12-21 2008-09-17 Decode Genetics EHF Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
WO2007135131A1 (en) * 2006-05-22 2007-11-29 Janssen Pharmaceutica N.V. Substituted pyrazinone derivatives for use as a medicine
EP2038256A1 (en) 2006-05-23 2009-03-25 TransTech Pharma, Inc 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ']-bipyridine and its use as a medicament
ATE538116T1 (en) 2006-05-29 2012-01-15 High Point Pharmaceuticals Llc 3-(1,3-BENYODIOXOL-5-YL)-6-(4-CYCLOPROPYLPIPERAZINE-1-YL)-PYRIDAZINE, ITS SALTS AND SOLVATES AND THEIR USE AS A HISTAMINE H3 RECEPTOR ANTAGONIST
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
TWI457122B (en) 2007-07-20 2014-10-21 Orion Corp 2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous system diseases
AR073628A1 (en) 2008-10-07 2010-11-17 Schering Corp BIARIL ANALOGS ESPIROAMINOOXAZOLINA AND ESPIROAMINODIAZOLINA MODULATORS OF ADRENERGIC RECEPTORS ALFA2C, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND USE OF THE SAME IN ALLERGIC RHINITIS, CARDIAC DISORDERS AND OTHER DISEASES
TW201024282A (en) 2008-11-20 2010-07-01 Orion Corp New pharmaceutical compounds
WO2011070177A2 (en) * 2009-12-11 2011-06-16 Baltic Technology Development, Ltd. Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators
CN103524413B (en) * 2012-07-04 2016-04-20 江苏先声药物研究有限公司 hydrogenated acridine derivative and application thereof
JOP20200052A1 (en) * 2013-12-19 2017-06-16 Bayer Pharma AG Substituted piperidinyl-tetrahydroquinolines and their use as alpha-2c adrenoreceptor antagonists
EP3125891A4 (en) * 2014-03-31 2017-08-09 Mirx Pharmaceuticals, LLC Novel hdmx inhibitors and their use for cancer treatment
WO2016135139A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135140A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135138A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135137A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
CN107337641B (en) * 2017-07-01 2020-04-28 广东医科大学 4-flexible amino-2-arylvinyl quinoline derivative and preparation method and application thereof
EP4398902A1 (en) * 2021-09-07 2024-07-17 Gismo Therapeutics, Inc. Compounds and pharmaceutical compositions comprising inhibitors of amyloid peptide interactions with glycosaminoglycans, methods of treatment, and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds

Also Published As

Publication number Publication date
WO2001064645A3 (en) 2001-12-27
EE200200490A (en) 2003-12-15
NO20024159L (en) 2002-08-30
EP1263733A2 (en) 2002-12-11
JP2003525274A (en) 2003-08-26
ZA200206956B (en) 2003-12-01
AU2001239331A1 (en) 2001-09-12
WO2001064645A2 (en) 2001-09-07
CN1468224A (en) 2004-01-14
MXPA02008402A (en) 2003-10-14
CZ20022880A3 (en) 2003-06-18
PL357874A1 (en) 2004-07-26
HUP0204458A2 (en) 2003-04-28
BR0108816A (en) 2002-12-10
FI20000480A0 (en) 2000-03-01
CA2400657A1 (en) 2001-09-07
RU2002125944A (en) 2004-02-27
IL151093A0 (en) 2003-04-10
AR034249A1 (en) 2004-02-18
KR20020089372A (en) 2002-11-29
SK12332002A3 (en) 2003-07-01
NO20024159D0 (en) 2002-08-30
HUP0204458A3 (en) 2004-07-28

Similar Documents

Publication Publication Date Title
PE20011084A1 (en) QUINOLINE DERIVATIVES AS ALPHA-2 ANTAGONISTS
PE20001467A1 (en) DERIVATIVES OF 4-PHENYLPYRIDINE AS ANTAGONISTS OF THE NEUROQUININ RECEPTOR
PE20021155A1 (en) QUINOLINE DERIVATIVES AS ANTAGONISTS OF NEUROPEPTIDES AND
AR062209A1 (en) MGLUR5 METABOTROPIC GLUTAMATE RECEPTORS MODULATING PIRAZOLOPIRIMIDINES, PROCESS FOR PREPARATION, MEDICATIONS CONTAINING THEM AND USES IN THE PREVENTION AND / OR TREATMENT OF ACUTE AND CHRONIC NEUROLOGICAL DISORDERS.
PE20120418A1 (en) DERIVATIVES OF PYRID [2,3-b] PIRAZINE AS INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP)
PE20020485A1 (en) QUINOLINE AND QUINAZOLINE DERIVATIVES AS NEUROPEPTIDE ANTAGONISTS AND
ES2530943T3 (en) Chromenone derivatives with antitumor activity
AR029301A1 (en) COMPOUNDS DERIVED FROM BIARILO, METHODS FOR THEIR PREPARATION COMPOSITIONS THAT CONTAIN THEM, THEIR USE AS AGONISTS IN BETA-ADRENO-ATIPIC RECEIVERS
PE20040081A1 (en) DERIVATIVES OF QUINOLINE AND ISOQUINOLINE AS INHIBITORS OF THE SECRETION OF CYTOKINES IL-8
PE20050482A1 (en) DIHYDROBENZOFURANIL ALKANAMIDE DERIVATIVES
PE20090509A1 (en) THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS
PE20010039A1 (en) CARBAMIC ACID ESTER DERIVATIVES AS AGONISTS AND / OR ANTAGONISTS OF THE METABOTROPIC GLUTAMATE RECEPTOR
PE18295A1 (en) PIPERIDINE DERIVATIVE
AR049331A1 (en) DERIVATIVES OF IMIDAZOPIRIDINES, IMIDAZOQUINOLINAS AND IIMIDAZONAFTIRIDINAS REPLACED WITH AMIDAS AS MODULATORS OF BIOSYNTHESIS OF CYTOKINES. PHARMACEUTICAL COMPOSITIONS.
PE20010741A1 (en) PIPERAZINE DERIVATIVES AS ANTAGONISTS OF TACHYCININS
PE20020657A1 (en) AMIDE DERIVATIVES OF 1,4-DISUSTITUTED PIPERIDINS OF FORMULA (I)
AR050281A1 (en) DERIVATIVES OF INDOL, INDAZOL AND INDAZOLINA. PROCESSES OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS
AR077147A1 (en) BICYCLE AND TRICICLIC COMPOUNDS AS KAT II INHIBITORS
PE20080182A1 (en) PIRROLO-QUINOXALINONE DERIVATIVES AS ANTIBACTERIALS
PE20030603A1 (en) QUINOLINE DERIVATIVES
AR049995A1 (en) A PROCEDURE FOR THE PREPARATION OF DERIVATIVES N-PIPERIDINO-1,5-DIFENILPIRAZOL-3-CARBOXAMIDA
AR054102A1 (en) DERIVATIVES OF FENIL-PIPERAZINA-METANONA. PROCESSES OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS
AR047958A1 (en) DERIVATIVES OF 1-BENCIL-5-PIPERAZIN-1-IL-3,4 DIHIDRO-1H-QUINAZOLIN-2-ONA AND ITS DERIVATIVES 1H-BENZO (1,2,6) TIADIAZINA-2,2-DIOXIDES AND 1,4 -DIHIDRO-BENZO (D) (1,3) OXAZINAS-2-ONA, AS MODULATORS OF THE 5-HT RECEIVER, FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM.
PE20020258A1 (en) DERIVATIVES OF 4-PHENYL-PYRIDINE AS ANTAGONISTS OF THE NEUROQUININ 1 (NK-1) RECEPTOR
PE20040828A1 (en) BENZOXAZINONES AS MODULARS OF 5-HYDROXITRIPTAMINE (5-HT)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal